| Title | Innovative treatment strategies for non-Hodgkin's lymphoma and multiple myeloma. | | Author(s) | Borden EC | | Institution | Department of Medicine, University of Maryland, Baltimore 21201-1595. | | Source | Semin Oncol 1994 Dec; 21(6 Suppl 14):14-22. | | MeSH | Animals
Clinical Trials, Phase I
Clinical Trials, Phase II
Combined Modality Therapy
Humans
Interferon-alpha
Lymphoma, Non-Hodgkin
Multiple Myeloma
Randomized Controlled Trials
| | Abstract | Interferon-alfa (IFN-alpha) has been evaluated in non-Hodgkin's lymphoma and multiple myeloma. The preclinical evidence that IFN-alpha has antitumor activity against non-Hodgkin's lymphoma includes genetic deficits in IFN-alpha production in patients with non-Hodgkin's lymphoma, direct antiproliferative effects of IFN-alpha in stem cell assays, and beneficial effects of combined IFN-alpha and chemotherapy in experimental models. Interferon-alfa was active in phase I and II studies of patients receiving prior chemotherapy for non-Hodgkin's lymphoma, particularly those with low- to intermediate-grade lymphoma. The results of randomized studies suggest that adding IFN-alpha to chemotherapy as either induction or maintenance therapy may improve the outcome in patients with previously untreated non-Hodgkin's lymphoma. Interferon-alfa also appears to have activity as a single agent in patients with multiple myeloma, and eventually may have a role as maintenance therapy in patients with multiple myeloma. Collectively, these studies reveal a trend toward using IFN-alpha in patients with smaller hematologic tumor burden instead of reserving it as a last-resort measure. | | Language | eng | | Pub Type(s) | Journal Article
Review
| | PubMed ID | 7992095 |
|
